BIOLIFE SOLUTIONS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $96.2M | $74.6M | $68.0M | $76.2M | $119.2M |
| Cost of revenue | $34.1M | $24.6M | $26.7M | — | — |
| Gross profit | $62.1M | $50.1M | $41.3M | — | — |
| Research and development | $7.6M | $4.8M | $5.5M | $8.7M | $11.8M |
| Operating income | -$16.6M | -$4.5M | -$17.2M | -$5.9M | -$35.2M |
| Pretax income | -$12.1M | -$8.8M | -$12.2M | -$4.8M | -$27.8M |
| Income tax expense | $49,000 | -$38,000 | -$64,000 | -$5.2M | -$20.1M |
| Net income | -$4.6M | -$20.2M | -$68.0M | -$139.8M | -$8.9M |
| Balance Sheet | |||||
| Cash and equivalents | $33.0M | $91.5M | $27.9M | $19.4M | $69.9M |
| Current assets | $136.6M | $148.8M | $120.6M | $138.5M | $126.1M |
| Total assets | $405.9M | $399.5M | $412.7M | $450.2M | $554.3M |
| Current liabilities | $23.0M | $32.7M | $42.2M | $44.6M | $42.7M |
| Total liabilities | $34.0M | $50.6M | $75.1M | $86.0M | $76.2M |
| Total debt | $5.0M | $16.0M | $23.9M | $25.8M | $7.2M |
| Stockholders' equity | $371.9M | $348.9M | $337.7M | $364.2M | $478.0M |
| Cash Flow Statement | |||||
| Cash from operations | $20.1M | $8.4M | -$12.5M | -$8.5M | -$4.6M |
| Depreciation and amortization | $2.3M | $5.2M | $7.1M | $6.8M | $4.7M |
| Stock-based compensation | $23.0M | $30.9M | $33.2M | $25.3M | $14.0M |
| Capital expenditure | $9.5M | $3.2M | $6.4M | $10.4M | $8.4M |
| Free cash flow | $10.6M | $5.2M | -$18.9M | -$18.9M | -$13.0M |
| Impairments | $0 | $0 | $15.5M | $110.4M | $0 |
Shares outstanding 48.9M · Free float 83.0%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.